NCT04147078

Personalized DC Vaccine for Postoperative Cancer

Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Sichuan University · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Detailed description

Postoperative patients with pathological confirmed locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer and colorectal cancer with standard adjuvant treatment are enrolled. This is a prospective exploratory trial. Patients' tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.

Conditions

• Gastric Cancer
• Hepatocellular Carcinoma
• Non-Small-Cell Lung Cancer
• Colon Rectal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	DC vaccine subcutaneous administration	subcutaneous administration

Timeline

• Start date: 2019-06-01
• Primary completion: 2025-12-31
• Completion: 2026-06-01
• First posted: 2019-10-31
• Last updated: 2025-02-28

Locations

1 site across 1 country: China